Compare ClearPoint Neuro Inc (CLPT) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs LyondellBasell Industries NV — how do they compare? ClearPoint Neuro Inc trades at $15.22 (market cap $454.21M), while LyondellBasell Industries NV trades at $63.87 (market cap $20.67B). The key difference: LyondellBasell Industries NV is far larger — about 45.5× ClearPoint Neuro Inc's market cap, and LyondellBasell Industries NV pays a 6.44% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | LYB | |
|---|---|---|
Market Cap | $454.21M | $20.67B |
Sector | Health | Basic Materials |
52-Week High | $29.60 | $82.38 |
52-Week Low | $8.66 | $42.28 |
Enterprise Value | $488.79M | $32.26B |
Dividend Yield | — | 6.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.18, up 4.19% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings expectations with a $0.38 loss per share. Despite negative profitability metrics, analyst consensus remains unanimously bullish with 100% buy ratings. Recent news highlights regulatory progress with partners and expansion of the drug delivery ecosystem.
The stock presents a high-risk opportunity with strong analyst support despite current losses. Investment thesis hinges on successful commercialization of neuro drug delivery technologies and partnership execution. Key risks include persistent negative cash flow from operations and delayed revenue ramp-up from new facilities. Upside depends on translating regulatory momentum into sustainable revenue growth.
LyondellBasell Industries (LYB) trades at $62.79, up 0.22% today, with a bullish technical outlook supported by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $4.30 versus $3.44 estimated, driven by improved margins from supply disruptions. However, 2025 fundamentals show challenges, including a net loss of $745 million and negative profit margins, though cash flow from operations remains positive at $2.26 billion.
The stock offers potential upside to the $70.56 analyst consensus target, with 46% of analysts rating it a buy, but faces risks from volatile chemical markets and high debt. Investor sentiment is mixed amid earnings recovery signs and macroeconomic pressures on demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
